Securities Report – 23rd Fiscal Period (2025/04/01 – 2026/03/31)
NQ Score
70/100
N1 Content Completeness
80
AI Summary (NQ-processed)
Ribomic Inc. has filed its Securities Report for the 23rd fiscal period (April 1, 2025 – March 31, 2026), disclosing financial performance, corporate governance, and future outlook.
AI Analysis
Frequently Asked Questions
- Q: What is a securities report?
- A: A mandatory disclosure document filed by listed companies, containing financial results and business risks.
- Q: What is Ribomic's core technology?
- A: Ribomic specializes in RNA-based therapies for cancer and genetic diseases, with proprietary delivery systems.
- Q: Where can I read the report?
- A: Available on Ribomic's IR website or Japan's EDINET database.